Brain tumour clinical trial title

Trabectedin for Recurrent Grade II/III Meningioma EORTC

Brain tumour type

Meningioma, 

Website

clinicaltrials.gov/ct/show/NCT02234050

Description:

This is a multicentre, interventional, randomized, open label and comparative phase II trial that will assess whether trabectedin shows antitumour activity in patients with recurrent high grade (grade II or III) meningioma. The primary endpoint of the study is progression-free survival. Secondary objectives will include progression-free survival at 6 months, best overall response, safety and quality of life of the patients.

Date added: 26th September 2015

Open/Closed: Open

Trial ends: July 2017

Provider

Contact details

Sarah Nuyens :



E-mail: 1320@eortc.be
Telephone: